Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. more
Time Frame | PHIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.91% | -3.39% | 0.2% |
1-Month Return | 18.94% | -1.92% | 2.72% |
3-Month Return | -26.94% | -10.54% | 7.31% |
6-Month Return | -59.02% | -4.47% | 10.44% |
1-Year Return | -60.91% | 4.06% | 27.53% |
3-Year Return | -97.86% | 0.94% | 30.88% |
5-Year Return | -99.65% | 36.67% | 89.21% |
10-Year Return | -100% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 21.00K | 4.36K | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":20.77,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 4.30M | 183.00K | 192.00K | 193.00K | 6.33M | [{"date":"2019-12-31","value":67.91,"profit":true},{"date":"2020-12-31","value":2.89,"profit":true},{"date":"2021-12-31","value":3.03,"profit":true},{"date":"2022-12-31","value":3.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 21.00K | (183.00K) | (192.00K) | (193.00K) | (6.33M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-871.43,"profit":false},{"date":"2021-12-31","value":-914.29,"profit":false},{"date":"2022-12-31","value":-919.05,"profit":false},{"date":"2023-12-31","value":-30152.38,"profit":false}] |
Gross Margin | 100.00% | (4195.32%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-4195.32,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 9.01M | 8.79M | 13.51M | 11.46M | 4.49M | [{"date":"2019-12-31","value":66.67,"profit":true},{"date":"2020-12-31","value":65.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.83,"profit":true},{"date":"2023-12-31","value":33.25,"profit":true}] |
Operating Income | (8.99M) | (8.79M) | (13.51M) | (11.46M) | (10.82M) | [{"date":"2019-12-31","value":-898700000,"profit":false},{"date":"2020-12-31","value":-879300000,"profit":false},{"date":"2021-12-31","value":-1351100000,"profit":false},{"date":"2022-12-31","value":-1146200000,"profit":false},{"date":"2023-12-31","value":-1082400000,"profit":false}] |
Total Non-Operating Income/Expense | - | (2.00K) | 215.00K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (8.91M) | (8.79M) | (13.29M) | (11.48M) | (10.83M) | [{"date":"2019-12-31","value":-890800000,"profit":false},{"date":"2020-12-31","value":-879400000,"profit":false},{"date":"2021-12-31","value":-1328700000,"profit":false},{"date":"2022-12-31","value":-1148000000,"profit":false},{"date":"2023-12-31","value":-1082600000,"profit":false}] |
Income Taxes | (67.00K) | (134.30K) | (75.00K) | (175.00K) | 204.00K | [{"date":"2019-12-31","value":-32.84,"profit":false},{"date":"2020-12-31","value":-65.83,"profit":false},{"date":"2021-12-31","value":-36.76,"profit":false},{"date":"2022-12-31","value":-85.78,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | (8.66M) | (13.21M) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-865970300,"profit":false},{"date":"2021-12-31","value":-1321200000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (8.91M) | (8.79M) | (13.29M) | (11.48M) | (11.66M) | [{"date":"2019-12-31","value":-890800000,"profit":false},{"date":"2020-12-31","value":-879400000,"profit":false},{"date":"2021-12-31","value":-1328700000,"profit":false},{"date":"2022-12-31","value":-1148000000,"profit":false},{"date":"2023-12-31","value":-1166200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.84M) | (8.79M) | (13.21M) | (11.30M) | (10.83M) | [{"date":"2019-12-31","value":-884100000,"profit":false},{"date":"2020-12-31","value":-879400000,"profit":false},{"date":"2021-12-31","value":-1321200000,"profit":false},{"date":"2022-12-31","value":-1130500000,"profit":false},{"date":"2023-12-31","value":-1082600000,"profit":false}] |
EPS (Diluted) | (115.79) | (15.13) | (9.32) | (10.08) | (6.62) | [{"date":"2019-12-31","value":-11579,"profit":false},{"date":"2020-12-31","value":-1513,"profit":false},{"date":"2021-12-31","value":-932,"profit":false},{"date":"2022-12-31","value":-1008,"profit":false},{"date":"2023-12-31","value":-661.82,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PHIO | |
---|---|
Cash Ratio | 5.87 |
Current Ratio | 6.38 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PHIO | |
---|---|
ROA (LTM) | -61.07% |
ROE (LTM) | -126.86% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PHIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PHIO | |
---|---|
Trailing PE | NM |
Forward PE | 0.31 |
P/S (TTM) | 48.01 |
P/B | 0.61 |
Price/FCF | NM |
EV/R | 172.20 |
EV/Ebitda | 0.61 |
Phio Pharmaceuticals Corp (PHIO) share price today is $2.76
Yes, Indians can buy shares of Phio Pharmaceuticals Corp (PHIO) on Vested. To buy Phio Pharmaceuticals Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Phio Pharmaceuticals Corp (PHIO) via the Vested app. You can start investing in Phio Pharmaceuticals Corp (PHIO) with a minimum investment of $1.
You can invest in shares of Phio Pharmaceuticals Corp (PHIO) via Vested in three simple steps:
The 52-week high price of Phio Pharmaceuticals Corp (PHIO) is $10.35. The 52-week low price of Phio Pharmaceuticals Corp (PHIO) is $2.17.
The price-to-earnings (P/E) ratio of Phio Pharmaceuticals Corp (PHIO) is
The price-to-book (P/B) ratio of Phio Pharmaceuticals Corp (PHIO) is 0.61
The dividend yield of Phio Pharmaceuticals Corp (PHIO) is 0.00%
The market capitalization of Phio Pharmaceuticals Corp (PHIO) is $2.02M
The stock symbol (or ticker) of Phio Pharmaceuticals Corp is PHIO